Publications & Presentations in the therapeutic area :

Population pharmacokinetic – pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin

Snelder N., Drenth H.J., Riber Bergmann K., Wood N.D., Hibberd M., Scott G. Population pharmacokinetic – pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin. Br J Clin Pharmacol: 1–13, 2019. [Link to publication]

Exploration of alternative regorafenib regimens to manage hand – foot skin reaction

Ploeger B., Hoefman S., Ruppert M., Vis P., Zisowsky J., Grothey A., Cutsem E., Dochy E.v., Cleton A. Exploration of alternative regorafenib regimens to manage hand – foot skin reaction. European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer, 2019. [Link to publication]

A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy

Dejongh J. Ahsman M.& Snelder N. A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy. PAGE 2019/ IATDMCTS 2019. [Link to publication]

Evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure

Ploeger B., Cleton A., Keunecke A., Bruix J., Meinhardt G. Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). The American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, 2017.

Exposure-response relationship of regorafenib efficacy

Solms A., Reinecke I., Fiala-Buskies S., Keunecke A., Drenth H.J., Bruix, J., Meinhardt G., Cleton A., Ploeger, B. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. European Journal of Pharmaceutical Sciences: S149-S153, 2017. [Link to publication]

PKPD modelling of the relationship between testosterone and PSA

Snelder N., Drenth H., Bergmann K., Wood N., Hibberd M. and Scott G., PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin. What is the optimal testosterone level?, PAGE.(2015) [Link to publication]

A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice

Jongh J.d. and Ploeger B., A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice. Noordwijkerhout.(2010).

Marginal increase of sunitinib exposure

Erp N.P.v., Baker S.D., Zandvliet A.S., Ploeger B.A., Hollander M.d., Chen Z., Hartigh J.d., Konig-Quartel J.M., Guchelaar H.J. and Gelderblom H., Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemother Pharmacol, 29: 29, 2010.

Expertise